Advertisement

Topics

Search Results for "CT P6 Celltrion"

20:21 EST 8th February 2016 | BioPortfolio

Matching Channels

None

Matching News

INTERVIEW: The Biosimilar Brain - Celltrion’s Dr. Stanley Hong

South Korean firm Celltrion Healthcare is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar, Remsima (infliximab), which was rolled out across Europe ...

Early Approvals Pave Smooth Biosimilar Path For Celltrion, Samsung

South Korea's Celltrion and Samsung Bioepis are competing hard to grab a slice of the burgeoning global biosimilar market. Celltrion’s Remicade biosimilar has already been widely launched and may on...

Hospira/Celltrion: Don't Let U.S. Biosimilar Law's Questions 'Percolate'

"Further percolation will not advance the law," Hospira and Celltrion said, insisting that "settling the issue will spur competition."

Celltrion submits rituximab biosimilar application to EMA

South Korean biotechnology company Celltrion has, according to Business Korea, submitted a second biosimilar application to the European Medicines Agency (EMA).

Celltrion to use cloud-based technology to boost biosimilar trials

Korean biopharmaceutical company Celltrion is to start using cloud-based technology to accelerate development…

Celltrion seeks EU approval for rituximab biosimilar

Korean drugmaker Celltrion filed for approval from the European Medicines Agency for CT-P10, a biosimilar for the monoclonal  -More- 

Biosimilar Launch Notification: Celltrion Claims Loophole In Remicade Suit

Celltrion contends that since it provided its infliximab biosimilar application to Janssen it doesn’t have to wait until FDA approval to provide 180-day notice of commercial launch.

Celltrion files IPR against Genentech

Celltrion Inc. (KOSDAQ:068270) filed an inter partes review (IPR) petition with the U.S. Patent and Trademark Office challenging a patent from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) t...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement